Likarda is a cell therapy company developing enabling technologies for the delivery of cell therapies to improve their efficacy and provide patients with sustainable reversal for their chronic or fatal diseases. Likarda’s revolutionary technology to coat cells with inert hydrogels, called Core-Shell Spherification® (CSS™), is a customizable platform to deliver and maintain cells in their intended target location within the body, while keeping cells viable by protecting them from destruction.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Diabetes Cell Therapy
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
